CSIMarket
 


Kindred Biosciences Inc   (KIN)
Other Ticker:  
 

Cumulative Kindred Biosciences Inc 's Quick Ratio for Trailing Twelve Months Period

KIN's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

KIN Quick Ratio for Trailing Twelve Months Period

(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Dec 31 2020)
IV. Quarter
(Sep 30 2020)
III. Quarter
(Jun 30 2020)
II. Quarter
Y / Y Current Liabilities Growth 62.04 % -35.73 % -32.55 % -47.28 % -9.02 %
Y / Y Cash & cash equivalent Growth 10.55 % 18.14 % -18.59 % -28.71 % -15.66 %
Quick Ratio for Trailing Twelve Months Period 8.59 9.76 8.22 7.79 7.46
Total Ranking # 430 # 326 # 346 # 324 # 327
Seq. Current Liabilities Growth 71.86 % -4.99 % 29.36 % -23.28 % -31.84 %
Seq. Cash & cash equivalent Growth 17.49 % 8.18 % -6.35 % -7.12 % 25.56 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Jun 30 2021
On the trailing twelve months basis Due to jump in Current Liabilities in the II. Quarter to $11 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 8.59 below Kindred Biosciences Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Major Pharmaceutical Preparations industry 224 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Kindred Biosciences Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about KIN
Quick Ratio KIN in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 225
Sector # 339
S&P 500 # 541


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
29.32 15.06 7.46
(Jun 30 2016)   (Jun 30 2020)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Jun 30 2021, within Major Pharmaceutical Preparations Industry Quick Ratio for Trailing Twelve Months Period
Eledon Pharmaceuticals Inc   23.60 
Disc Medicine Inc   23.41 
Kezar Life Sciences Inc   23.39 
Gain Therapeutics inc  22.86 
Viking Therapeutics Inc   22.75 
Point Biopharma Global Inc   22.05 
Monopar Therapeutics Inc   22.01 
Avidity Biosciences Inc   21.66 
Enliven Therapeutics Inc   21.50 
Allakos Inc   21.49 
Akero Therapeutics Inc   21.26 
Kura Oncology Inc   21.18 
Savara Inc   21.07 
Werewolf Therapeutics Inc   20.96 
Mustang Bio inc   20.77 
Sage Therapeutics Inc   20.71 
Milestone Pharmaceuticals inc   20.62 
Neurogene Inc   20.40 
89bio Inc   19.56 
Applied Molecular Transport Inc   19.55 
Aerovate Therapeutics Inc   19.44 
Immuron Limited  19.33 
Oragenics Inc   19.16 
Hoth Therapeutics Inc   19.13 
Neximmune Inc   19.08 
Praxis Precision Medicines Inc   19.06 
Tonix Pharmaceuticals Holding Corp   19.02 
Trillium Therapeutics Inc   18.96 
Astria Therapeutics inc   18.83 
Myokardia Inc   18.80 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com